Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CPSS 6.63 - reports Q3 tomorrow...
https://finance.yahoo.com/news/cps-host-conference-call-third-183500719.html
SKAS 2.54 - new bid of '10K @ $2.60' while having an average daily volume of 213 shares.
https://www.otcmarkets.com/stock/SKAS/quote
Might be wade deciding to wade into some low volume VALUE, perhaps???
ADVM 2.58 in afterhours on late Friday news:
https://docoh.com/news/benzinga/23202094/adverum-presents-2-year?fromCompany=1501756
Also what is "Zebra's Law"?
Nice call on PALT but I missed the run trying to catch a dip to 2.70...oh well...what I see now in PALT's ludicrous pps-run is just more evidence this market is primed for a serious reality check
SGMA 8.80 - also like 8's.
It's all confusing and dd into the BNTX filings shows BNTX with many future irons in the fire, undoubtedly some partnering with Genevant. So longerterm, the partnership with BNTX might realize revenue?
And this from the GRTS 10-K - page 33:
License Agreement with Arbutus Biopharma Corporation
...As part of our collaboration, we have identified an LNP formulation that we believe will be optimal for use in our Phase 1/2 clinical trial of GRANITE and SLATE. This LNP formulation is currently being used by third parties in human clinical trials in the United States...
https://docoh.com/filing/1656634/0001564590-21-012260/GRTS-10K-2020FY
Who knew? And the filing is from March...
If Genevant sublicenses the intellectual property, licensed by us to Genevant, we are entitled to receive upon the commercialization of a product developed by such sublicensee the lesser of 20% of the revenue received by Genevant for sublicensing and tiered, low single-digit royalties on product sales by the sublicensee.
Does this mean we can eliminate PFE/BNTX from providing any revenue whatsoever to ABUS as ABUS has not recorded any revenue from Genevant to date? And the PFE/BNTX-vaccine has been commercialized for several quarters?
Welp, do you reckon it's so many vendors with so many shares selling this morning? More showing their 'true colors'...getting 'what they deserve'???
GLTO - added today at 3.83...appears GLTO should try to hire away NNVC's pr, promo, n prop crew, ya think?
Galecto's GB0139 Shows Favorable Safety and Tolerability Profile with Promising Changes in Efficacy Markers in Hospitalized COVID-19 Patients
https://docoh.com/news/benzinga/21665863/galectos-gb0139-shows?fromCompany=1800315
NNVC 6.30 - always thought NNVC was one of the more scammy bio's but they have built up a sizeable cash warchest thru all the covid pr's. It looks like your best outcome would be for them to do a healthy secondary @ $6+ into this ludiculous volume because I seriously doubt anyone will be able to corroborate their fish-story with a reciprocal pr from GILD (remdesivir)?
Might get interested in the $4's...just my two cents
Get up on in there, hweb, sign up n see if you can catch nuthin...lol
I agree, the numbers are pretty good for such a low-share-structure-tiny-market-cap-company in such a dyno sector with such HUGE potential. I signed up and will dig into the site and the fundys further...
PALT 3.06 - interesting...
https://www.paltalk.com/people/webapp/index.wmt
Has anyone become a member and could offer comments on the paltalk website? At first glance it appears to be a risque-hook-up-site...
Thanks value and I'll be focusing in on GME as the overall-barometer-stock for guaging the broad-markets?
GME - I can't recall any stock-pps failing so many 'value' tests so badly!
HBP - added 5.07 yesterday...recent Q of .54 eps and a not-so-distant buyout offer...
GLTO 4.03 - bought the dip at today's close. Another cashfatbiobust trading way less than cash...with a few irons on the fire, more specifically:
Galecto's GB0139 Shows Favorable Safety and Tolerability Profile with Promising Changes in Efficacy Markers in Hospitalized COVID-19 Patients
https://docoh.com/news/benzinga/21665863/galectos-gb0139-shows?fromCompany=1800315
Yes, I also saw some very peculiar trading activity of several stocks, up & down, in the closing minutes but don't think it had anything to do with options-expiration...and SNFCA doesn't offer option trading?
SNFCA 8.97 (+.91) - very strong close...
https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=snfca&insttype=&freq=9&show=&time=1
https://www.nasdaq.com/market-activity/stocks/snfca/latest-real-time-trades
Someone/group snatched a sizeable chunk right at the close? What's up with that?
'...this is a pandemic of the unvaccinated not anything else right now...'
I'm still holding about 70% of my investment-poke in cash even though several stocks on my watch are hitting my buy targets? This market is sooooooo primed to suffer some prolonged devastation and I'm guessing (knowing) these gullible-robinhooligans will jump ship more aggressively than they originally climbed aboard?
One more question:
Is GME at $200 the most (non-outright-scam) OBVIOUS short-proposition we have ever seen in our lifetimes?
In 2020, the death of old and sick people was declared… impermissible! Death suddenly had no place in the exceptional order of things American.
https://kunstler.com/clusterfuck-nation/ordeal-by-narrative/
OVID 3.48 - setup for a freeroll???
$3 netcash-per-share?
Takeda, going forward, to incur all research expenses?
Two Phase-3-commencement announcement catalysts upcoming in 2021?
Two, pivotal Phase 3 clinical studies of soticlestat for Dravet syndrome and Lennox-Gastaut syndrome, operated and funded by Takeda, are expected to commence in 2021. If successful, Takeda estimates that soticlestat could receive approval in its fiscal year 2023.
https://docoh.com/filing/1636651/0001564590-21-044455/OVID-8K/file/2
OVID 3.48 - setup for a freeroll???
$3 netcash-per-share?
Takeda, going forward, to incur all research expenses?
Two Phase-3-commencement announcement catalysts upcoming in 2021?
Two, pivotal Phase 3 clinical studies of soticlestat for Dravet syndrome and Lennox-Gastaut syndrome, operated and funded by Takeda, are expected to commence in 2021. If successful, Takeda estimates that soticlestat could receive approval in its fiscal year 2023.
https://docoh.com/filing/1636651/0001564590-21-044455/OVID-8K/file/2
OVID 3.48 - setup for a freeroll???
$3 netcash-per-share?
Takeda, going forward, to incur all research expenses?
Two Phase-3-commencement announcement catalysts upcoming in 2021?
Two, pivotal Phase 3 clinical studies of soticlestat for Dravet syndrome and Lennox-Gastaut syndrome, operated and funded by Takeda, are expected to commence in 2021. If successful, Takeda estimates that soticlestat could receive approval in its fiscal year 2023.
https://docoh.com/filing/1636651/0001564590-21-044455/OVID-8K/file/2
APT 7.62 - took a small loss on my previous stab at this one. Also I was not impressed with the recent numbers and after watching the college football stadiums the past two weekends...ditching the silly corona-kookout-maskerade...APT belongs back on the back heap of somewhere around $5 or less fair-value-pps imo.
CPSS 5.25 - doubled-down. BV $6.50, quarterly eps of $.39, recent buyout offer, hitting on all cylinders,
https://ir.consumerportfolio.com/news-releases/news-release-details/cps-announces-second-quarter-2021-earnings
and the used-car-market would appear to be getting even stronger as we hear new reports, daily, of 'chip shortages' and 'supply chain' disruptions?
What happen to sub royalties from Genevant
Great question? The Genevant website lists some substantial partnerships!
https://www.genevant.com/partnering/
But I can't find any revenue shown in ABUS filings coming from Genevant...
CPSS 5.85 - reassumed my position on the constant recent news of new car chip shortages. The used car market looks to remain strong for months more and CPSS has some stellar numbers.
Also, my crystalball shows the broad-markets sinking and few stocks will escape - but who knows - the broad markets might just go up everyday thruout eternity? Sheesh
This stock is tightly held by a few institutions, company insiders and from what I can ascertain, a strong group of retail investors unwilling to sell their shares cheap
Out of curiousity and a serious question, do you read the quarterly Q's and K filing? One of the pluses in NBIO is they do follow SEC compliance...but if one don't read then one don't know...n'est ce pas
old geezer
IKT 2.18 - took a closer look and not impressed. So many of these low-dollar biotechs are just dilution-scam-hucksters trying to mask-erade as being sophisticated.
The SURPRISE share dump at $3 on 6/15 when the pps had been $6 on the previous Friday was ugly ugly and the previous 10-K report filed on 4/1 makes no mention of the need for additional funding which should have been OBVIOUS to all, management and retail investor? Why not make mention of it in good faith as I think the current pps would be the same?
https://docoh.com/filing/1750149/0001193125-21-103715/IKT-8K/file/2
Do you know the Cash on Hand for ADVM? I do not, exactly, because of the "lease" numbers on the Balance Sheet. Can anyone here explain this to me? I assume these two numbers wash each other out leaving a final liability of approx. (23,500)?
Operating lease right-of-use assets 101,876 (asset)
Lease liability, net of current portion 125,361 (liability)
https://docoh.com/filing/1501756/0001628280-21-015877/ADVM-10Q-2021Q2
ok2buy, I searched for update details with regard to the partnership between Syracuse U, Allison Patteson, and a possible therapeutic answer to corona-kookout? I drew a blank?
Have you heard any recent positive update?
They've revised the previous need for $26M to needing $10 - $15M in the recent Q...
NEED FOR ADDITIONAL FINANCING:
Our current capital needs are estimated to be approximately $10-15 million. This will take us through Phase II clinical trials which is scheduled to begin in 2022 subject to the completion of phase 1 and FDA approval to proceed to phase 2.
https://www.otcmarkets.com/filing/html?id=15155687&guid=oJp1kFJoKOdkS3h
But at clinicaltrials.gov, I read clearly that Phase 1 results won't be fully known until 6/30/23???
https://www.clinicaltrials.gov/ct2/show/results/NCT04396717?term=pritumumab&draw=2&rank=1
Therefore, management remains flakily asleep-at-the-wheel at best...at worst...I shutter to think...that any one of us can get this at a lesser pps by simply applying a bit of patience, ya think?
CLBS 1.29 - are you watching this one? Another biobust trading well below book. I have a tripledown buy-order at 1.05 but with a bit more strength, I might get the chance to flip a few...
GLYC 1.99 - traded it a couple times recently for a few pennies, several irons in the fire, and remains high on my biobust watchlist.
"There are now six trials underway evaluating our lead clinical candidate, uproleselan, including three registration trials and three ISTs, which we anticipate will provide clinical data flow beginning in 2022.
https://docoh.com/news/benzinga/22346501/glycomimetics-reports?fromCompany=1253689
A few months ago, I'd have been way more aggressive at this pps in GLYC, but I'm convinced the indexes are waaaayyyyyy too high. And it's even probable that the robinhooligans will be just as overeager in their eventual selling as they've shown to be in their overeager buying???
CPSS 5.93 - took profit here...will wait for dip?
Reading many filings with verbage 'supply chain disruption...labor shortages'?
I'm convinced this is an ABSOLUTE result of the corona-kookout! Who wants to work 8 hrs. a day masked up to the gills AND be commanded to VAX???
On the subject of Who, they'll need to update their lyrics...
Meet the new boss
Not the same as the old boss
Much more demanding and stupider
ADVM 2.38 - BV 3.87 way better biobust-bottom-play than IKT 2.15 - BV 1.88 at this time...imo?
HBP 5.63 - joined in here for reasons you stated:
Earnings of .30/share in seasonally weak Q1 vs a loss last year. Then earnings of .54/share in seasonally stronger Q2 vs .06/share last year.
Yep, spectacular numbers and no one seems to care...
LUMO 9.64 - sold the remainder of my poke in this strength. Also sold a ton of other stuff as I just moved to about 75% cash.
#1. the indexes have NO BUSINESS being this high. NO BUSINESS!
#2. the covered-call-oppurtunities (my breadnbutter for 6 months+) have all but disappeared. An absolute broad market negative imo.
#3. a golden opp to sit back and watch for a bit...
Another fustercluck $$$-loser filing...why don't they raise the damn price making an attempt to show profit?
Negotiated into CEC's Clean Transportation Program – Up to $200 million in potential EVSE funding.
https://docoh.com/news/benzinga/22476976/beam-global-reports-fiscal?fromCompany=1398805
Weeeeeeeeeeee...will they ever make selling product (NOT PAPER) their #1 priority? Guess you can take CEO out of this previous paper-printing-scam but you can't take the paper-printing-scam out the CEO hahaha...
continue to watch...